At Bristol Myers Squibb, we are inspired by a single vision transforming patients lives through science. In oncology, hematology, immunology and cardiovascular disease and one of the most diverse and promising pipelines in the industry each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.
Overview
Mavacamten is an investigational agent intended to address a number of indications in Hypertrophic Cardiomyopathy (obstructive and non obstructive). This asset is expected to be a multi-billion dollar product over the next few years and will be a leading asset for BMS expanding Cardiovascular portfolio. The initial filing for oHCM is planned for Q1 2021 in the US and with breakthrough therapy designation (BTD), could potentially be approved for launch by August 2021. Current timeline for filing in EU expected to be Q2 2021, with potential approval in Q2/Q3 2022.
Position Description:
The Director, WW Commercial Mavacamten, will play a critical role on the WW Cardiovascular Commercial team in leading the development of the commercial strategy, ensuring launch readiness and ultimately launch success of mavacamten. This leader will report to the Worldwide mavacamten brand lead, and work closely with R&D, medical, HEOR, Access, BI&A, Regulatory, Global Product Supply, Corporate Affairs, Advocacy and other cross functional partners to deliver launch objectives for mavacamten. The Director may also be responsible for shaping Life Cycle Management, and in doing so, will need to work with Global Development to gain alignment and support the long term strategy.
Position Requirements:
The successful candidate needs to have multiple experiences of championing and leading commercial initiatives across multiple disease areas. This candidate should have demonstrated ability to implement and understand market analysis and assessments to drive strategic decisions. This individual should have successful launch experience either in major markets or another worldwide setting.
This individual will work closely with the broader mavacamten integrated leadership team, Clinical Development team, and others to ensure that the integrated learnings are rapidly applied and appropriate market development opportunities are being identified. The ability to identify commercial gaps and engage necessary stakeholders to assess strategic value, will be critical for the successful candidate to demonstrate.
Candidate should have exceptional interpersonal skills with the ability to manage relationships by leading and participating in multi-functional teams and excelling in a matrix environment. Competencies include Global Perspective, Strategic Planning, Pricing and Reimbursement, Influencing and Negotiating Skills, Brand Therapeutic Area Knowledge, Marketing Analytics, Market, Customer & Competitive insights, Brand and Positioning Management, and Seasoned Judgment. 8-10 years of Marketing or related experiences is a must. Experience in therapeutic areas such as cardiovascular, immunology, pulmonary arterial hypertension, or oncology are preferred.
* BA/BS required. MBA, PharmD, or other graduate experience strongly preferred
* Ability to understand the complexities of international marketplaces
* Demonstrated understanding of market access, HTA dynamics and value assessment approaches, with an unrelenting appetite to enhance the product development and commercialization process
* Experience in strategic marketing, medical and/or operational P&L roles, including product launch experience
* Demonstrated strategic capabilities, including deep experience with scenario planning, design-to-value, and decision analytics. Extensive knowledge of how specialty products are discovered and developed
* Understanding of specialty market(s) landscape, customer needs, trends, opportunities, and emerging technologies
* Demonstrated track record of leading, working with and integrating high performance, cross-functional teams
* Effective communicator (demonstrated public speaking a plus) with ability to influence key strategic decisions and demonstrated ability to successfully and effectively collaborate with R&D organization
* Strong analytical and strategic thinking required, with proven ability to execute change
Around the world, we are passionate about making an impact on the lives of patients with serious diseases. Empowered to apply our individual talents and diverse perspectives in an inclusive culture, our shared values of passion, innovation, urgency, accountability, inclusion and integrity bring out the highest potential of each of our colleagues.
Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.
New York, New York
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company’s products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd.
The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.